echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > BeiGene Announces a Phase 3 Clinical Trial of Baizean Combined with Chemotherapy as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma with Positive Main Results

    BeiGene Announces a Phase 3 Clinical Trial of Baizean Combined with Chemotherapy as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma with Positive Main Results

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BeiGene is a global biotechnology company focusing on the development and commercialization of innovative drugs worldwide
    .


    The company today announced the recommendation by the Independent Commission data detection, one used to evaluate the anti-PD-1 antibody Chak one hundred ® (natalizumab for Rayleigh) in combination with chemotherapy, compared to placebo in combination with chemotherapy as a treatment for recurrent or metastatic The Phase 3 RATIONALE 309 clinical trial of first-line therapy for patients with sexual nasopharyngeal carcinoma reached its primary endpoint in an interim analysis


    Baiji Divine tumor immunology Chief Medical Officer Ben Yong, MD, commented: "We are very excited to be observed in this Phase 3 clinical trials, one hundred Chak ® in combination with chemotherapy in patients with nasopharyngeal carcinoma capable of progression-free survival brought improve clinically significant
    .


    this indicates that the positive results obtained in item 5 percentage Chak ® 3 clinical trials, we are also an extensive clinical program of anti-PD-1 antibody for this potential difference to assess


    BeiGene plans to communicate the results of the trial with multiple regulatory agencies and announce the data at an upcoming medical conference
    .

    One hundred ZeAn ® combination chemotherapy vs Placebo combination chemotherapy for the treatment of recurrent or metastatic NPC patients RATIONALE 309 Clinical Trial

    RATIONALE 309 was a randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03924986), was to compare one hundred Chak ® in combination with gemcitabine and cisplatin versus placebo in combination with gemcitabine and cisplatin as first-line therapy for recurrent or metastatic NPC Effectiveness and safety
    .


    The primary endpoint of the trial is the PFS assessed by the IRC in the ITT population; key secondary endpoints include overall survival (OS), objective response rate (ORR) and duration of response (DoR) as assessed by IRC, as well as assessment by the investigator PFS


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.